Safety Study of TH9507 in Subjects With Stable, Type 2 Diabetes
Primary Purpose
Type 2 Diabetes
Status
Completed
Phase
Phase 2
Locations
Study Type
Interventional
Intervention
TH9507
Sponsored by

About this trial
This is an interventional treatment trial for Type 2 Diabetes
Eligibility Criteria
Inclusion Criteria:
- Male or postmenopausal or surgically sterilized female subjects, 50 years of age or older;
- Documented diagnosis of type 2 diabetes as defined by the American Diabetes Association;
- Diagnosis of type 2 diabetes for at least 3 months before screening;
- Subjects on stable diabetes treatment regimens (receiving oral hypoglycemics with or without insulin) for at least 2 months before screening;
- Screening and pre-randomization glycosylated hemoglobin (HbA1c) <10.0%, according to central laboratory;
- Body mass index (BMI) between 25 and 38 kg/m2
- Subjects willing to perform specified home blood glucose monitoring and comply with all study protocol requirements;
- Signed informed consent.
Exclusion Criteria:
- Serum creatinine >2 mg/dL;
- Fasting triglycerides >1000 mg/dL;
- Albuminuria >200 mg/24 hours;
- Positive mammography (if female) or prostate-specific antigen (PSA) or prostate examination for cancer (if male);
- Use of oral or parenteral glucocorticoids in the 30 days before screening;
- Use of any experimental or marketed growth hormone, growth hormone secretagogues, insulin-like growth factor-1 (IGF-1), or insulin-like growth factor binding protein-3 (IGFBP-3) during the previous 6 months;
- Subjects with two or more severe hypoglycemia episodes within the past 6 months, or any hospitalization or emergency room visit due to poor glycemic control within the past 6 months. Similarly, during the lead-in period, any subject with more than one severe hypoglycemic episode or any hospitalization or emergency room visit due to poor glycemic control will be excluded from randomization;
- History of or presence of active concomitant conditions or diseases (e.g., myocardial infarction, poorly controlled hypertension, thyroid disease, rheumatoid arthritis, seizure disorder, diabetic neuropathy, diabetic retinopathy [except subjects with only microaneurysms on fundus examination]) that would interfere with the protocol conduct and endpoint measurements;
- Subjects with a major surgical operation during the 30 days before screening;
- Subjects with known hypopituitarism, history of pituitary tumor/surgery, head irradiation, or severe head trauma;
- Current cancer or history of cancer, except non-melanomatous skin cancer;
- Subjects with active infection at any body site or a history of severe infection (requiring oral or parenteral treatment) during the 30 days before screening;
- Subjects with clinically significant abnormalities on screening laboratory evaluation (unless discussed with and approved by the medical monitor);
- Subjects with allergy to synthetic growth hormone products or their excipients;
- Subjects who had previously received growth hormones in any clinical trial;
- Participation in a trial of an experimental drug or device within 90 days before screening.
Sites / Locations
Outcomes
Primary Outcome Measures
Change from baseline in relative insulin response
Secondary Outcome Measures
Change from baseline in glycosylated hemoglobin (HbA1c)
Change in mean daily serum glucose concentrations
Home blood glucose will be obtained four times per day (before breakfast, lunch, and dinner, and at bedtime) using a standard blood glucose meter
Changes in the number of dose adjustments per week for insulin and/or oral hypoglycemic agents
Number of subjects with a change in the control of diabetes
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT01264497
Brief Title
Safety Study of TH9507 in Subjects With Stable, Type 2 Diabetes
Official Title
A Double-blind, Randomized, Parallel, Placebo-controlled 12-week Evaluation of the Safety of Two Doses of TH9507 in Subjects With Stable, Type 2 Diabetes Mellitus
Study Type
Interventional
2. Study Status
Record Verification Date
December 2010
Overall Recruitment Status
Completed
Study Start Date
February 2002 (undefined)
Primary Completion Date
November 2002 (Actual)
Study Completion Date
November 2002 (Actual)
3. Sponsor/Collaborators
Name of the Sponsor
Theratechnologies
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
The purpose of this study was to determine whether TH9507, a stabilized analogue of growth hormone-releasing factor (GRF), would have an effect on insulin sensitivity or control of diabetes in patients with type 2 diabetes.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Type 2 Diabetes
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Parallel Assignment
Masking
ParticipantInvestigator
Allocation
Randomized
Enrollment
55 (Actual)
8. Arms, Groups, and Interventions
Intervention Type
Drug
Intervention Name(s)
TH9507
Intervention Description
1 and 2 mg, sc daily for 12 weeks
Primary Outcome Measure Information:
Title
Change from baseline in relative insulin response
Secondary Outcome Measure Information:
Title
Change from baseline in glycosylated hemoglobin (HbA1c)
Title
Change in mean daily serum glucose concentrations
Description
Home blood glucose will be obtained four times per day (before breakfast, lunch, and dinner, and at bedtime) using a standard blood glucose meter
Title
Changes in the number of dose adjustments per week for insulin and/or oral hypoglycemic agents
Title
Number of subjects with a change in the control of diabetes
10. Eligibility
Sex
All
Minimum Age & Unit of Time
50 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Male or postmenopausal or surgically sterilized female subjects, 50 years of age or older;
Documented diagnosis of type 2 diabetes as defined by the American Diabetes Association;
Diagnosis of type 2 diabetes for at least 3 months before screening;
Subjects on stable diabetes treatment regimens (receiving oral hypoglycemics with or without insulin) for at least 2 months before screening;
Screening and pre-randomization glycosylated hemoglobin (HbA1c) <10.0%, according to central laboratory;
Body mass index (BMI) between 25 and 38 kg/m2
Subjects willing to perform specified home blood glucose monitoring and comply with all study protocol requirements;
Signed informed consent.
Exclusion Criteria:
Serum creatinine >2 mg/dL;
Fasting triglycerides >1000 mg/dL;
Albuminuria >200 mg/24 hours;
Positive mammography (if female) or prostate-specific antigen (PSA) or prostate examination for cancer (if male);
Use of oral or parenteral glucocorticoids in the 30 days before screening;
Use of any experimental or marketed growth hormone, growth hormone secretagogues, insulin-like growth factor-1 (IGF-1), or insulin-like growth factor binding protein-3 (IGFBP-3) during the previous 6 months;
Subjects with two or more severe hypoglycemia episodes within the past 6 months, or any hospitalization or emergency room visit due to poor glycemic control within the past 6 months. Similarly, during the lead-in period, any subject with more than one severe hypoglycemic episode or any hospitalization or emergency room visit due to poor glycemic control will be excluded from randomization;
History of or presence of active concomitant conditions or diseases (e.g., myocardial infarction, poorly controlled hypertension, thyroid disease, rheumatoid arthritis, seizure disorder, diabetic neuropathy, diabetic retinopathy [except subjects with only microaneurysms on fundus examination]) that would interfere with the protocol conduct and endpoint measurements;
Subjects with a major surgical operation during the 30 days before screening;
Subjects with known hypopituitarism, history of pituitary tumor/surgery, head irradiation, or severe head trauma;
Current cancer or history of cancer, except non-melanomatous skin cancer;
Subjects with active infection at any body site or a history of severe infection (requiring oral or parenteral treatment) during the 30 days before screening;
Subjects with clinically significant abnormalities on screening laboratory evaluation (unless discussed with and approved by the medical monitor);
Subjects with allergy to synthetic growth hormone products or their excipients;
Subjects who had previously received growth hormones in any clinical trial;
Participation in a trial of an experimental drug or device within 90 days before screening.
12. IPD Sharing Statement
Citations:
PubMed Identifier
28617838
Citation
Clemmons DR, Miller S, Mamputu JC. Safety and metabolic effects of tesamorelin, a growth hormone-releasing factor analogue, in patients with type 2 diabetes: A randomized, placebo-controlled trial. PLoS One. 2017 Jun 15;12(6):e0179538. doi: 10.1371/journal.pone.0179538. eCollection 2017.
Results Reference
derived
Learn more about this trial
Safety Study of TH9507 in Subjects With Stable, Type 2 Diabetes
We'll reach out to this number within 24 hrs